Blood Pressure-lowering Medication Research Articles

Hypoxia is not the primary mechanism contributing to exercise-induced proteinuria

IntroductionProteinuria increases at altitude and with exercise, potentially as a result of hypoxia. Using urinary alpha-1 acid glycoprotein (α1-AGP) levels as a sensitive marker of proteinuria, we examined the impact...

SUN-121 ASSOCIATION BETWEEN A NOVEL BIOMARKER, SERUM MIDKINE, AND ASYMPTOMATIC AND CLINICAL CARDIOVASCULAR DISEASE IN ELDERLY WOMEN

Elevated Midkine (MK) levels have been associated with acute cardiac events in patients with chronic heart failure. However its prognostic value in predicting subclinical and clinical outcomes of CVD in the elderly general population remains unknown. This study aims to determine the relationship between serum MK and asymptomatic measures and clinical outcomes of CVD in a large cohort of elderly women with long-term clinical follow-up. This was a prospective study of ageing women. Serum MK was measured in 1998 (baseline). The univariate association between baseline serum MK with baseline abdominal aortic calcification (AAC) 24 scores was analysed using Spearman’s correlation. Differences in baseline AAC24 scores, change in AAC24 scores at 5 years, and common carotid artery intimal medial thickness (CCA-IMT) at 3 years between medians of serum MK were assessed using analysis of covariance, adjusting for age, body mass index (BMI), baseline estimated glomerular filtration rate (eGFR), smoking history, diabetes, use of blood pressure lowering medications, use of statins, calcium treatment code and prevalent atherosclerotic vascular disease (ASVD). Associations between baseline serum MK and the occurrence of atherosclerotic plaques at 3 years, and atherosclerotic vascular disease (ASVD)-related hospitalisations and deaths at 14.5 years as a composite outcome were examined using logistic and Cox regression analyses respectively, adjusting for similar risk factors. The baseline cohort consisted of women aged over 70 years, with a median age of 75. Throughout the follow-up period of 15 years, there were a total of 206 deaths, and 225 ASVD-related hospitalisations and deaths. Baseline serum MK was correlated with baseline AAC24 scores in the univariate analysis (r = 0.111, p = 0.035). Baseline AAC24 scores were not significantly different between below and above-median baseline serum MK (below-median: 3.15 ± 0.26 vs above-median: 3.30 ± 0.27, p = 0.684), however the increase in AAC24 scores at 5 years was significantly higher in participants with above-median baseline serum MK as compared to those with below-median baseline serum MK (below median: 0.90 ± 0.18 vs above-median 1.64 ± 0.20, p = 0.007) after multivariable-adjustment. At 3 years, mean and maximum CCA-IMT were significantly greater in participants with above-median baseline serum MK as compared to those with below-median baseline serum MK after multivariable adjustment (below median: 0.769 ± 0.011 mm vs above-median: 0.802 ± 0.011 mm, p = 0.035; below-median: 0.910 ± 0.012 mm vs above-median: 0.951 ± 0.013 mm, p = 0.024, respectively), however above-median baseline serum MK was not associated with an increased risk of occurrence of atherosclerotic plaques (odds ratio = 0.99, 95% CI = 0.63-1.55, p = 0.964). Compared to below-median, above-median baseline serum MK was associated with a 1.3-fold increased risk of ASVD-related hospitalisations and deaths at 14.5 years (hazard ratio = 1.37, 95% CI = 1.05, 1.80, p = 0.022) after adjusting for known risk factors. In older women, elevated serum MK is associated with AAC outcomes and asymptomatic measures and clinical outcomes of ASVD. These results suggest that MK could be potential risk factor for CVDs, and further prospective studies are needed to determine the prognostic importance of elevated MK with CVD clinical outcomes.

SUN-120 ASSOCIATION BETWEEN SERUM MIDKINE AND RENAL OUTCOMES IN ELDERLY WOMEN

Midkine (MK) is heparin-binding cytokine which has been shown to mediate kidney injury and dysfunction via its immunomodulatory functions such as neutrophil and macrophage trafficking, lymphocyte activation, and induction of chemokines. While this has been demonstrated in a number of experimental studies, the extent of the association between Midkine and kidney disease at the population level remains largely unknown. The aims of this study were to determine the association between serum MK and longitudinal changes in kidney function and chronic kidney disease (CKD)-related clinical events in a large cohort of elderly women with long-term clinical follow-up. This was a prospective study of ageing women. Serum MK was measured in 1998 (baseline). Associations between baseline serum MK with change in estimated glomerular filtration rate (eGFR) at 5 and 10 years were analysed using linear regression analyses, adjusting for age, body mass index (BMI), diabetes, use of blood pressure lowering medications, use of statins and prevalent atherosclerotic vascular disease (ASVD). Associations between baseline serum MK and rapid renal decline at 5 years, defined as an annual eGFR decline of greater than 3 mL/min/1.73m2, and CKD-related hospitalisations and deaths at 14.5 years as a composite outcome were examined using logistic and Cox regression analyses respectively, adjusting for similar risk factors. The baseline cohort consisted of women aged over 70 years, with a median age of 75. Throughout the follow-up period of 15 years, there were a total of 206 deaths, and 46 CKD-related hospitalisations and deaths. Baseline serum MK was not associated with 5 and 10 year eGFR change (standardised β coefficient = -0.070, 95% CI = -3.548-0.843, p = 0.226; standardised β coefficient = -0.116, 95% CI = -6.470-0.514, p = 0.094, respectively), or the risk of rapid renal decline at 5 years (odds ratio = 1.85, 95% CI = 0.76-4.49, p = 0.175) in multivariable-adjusted models. Compared to below-median, above-median baseline serum MK was associated with a two-fold increased risk of CKD-related hospitalisations and deaths at 14.5 years (hazard ratio = 1.96, 95% CI = 1.07-3.62, p = 0.030) after adjusting for known risk factors. In older women with mild to moderate renal dysfunction, elevated serum MK is associated with CKD-related hospitalisation and death events. Further prospective studies are needed to determine the prognostic importance of increased MK activity with CKD.

Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China.

Despite improvements in diagnostic and therapeutic interventions to combat cardiovascular disease (CVD) in recent decades, there are significant ongoing access gaps and sex disparities in prevention that have not been adequately quantified in China. A representative, cross-sectional, community-based survey of adults (aged ≥45 years) was conducted in 7 geographic regions of China between 2014 and 2016. Logistic regression models were used to determine sex differences in primary and secondary CVD prevention, and any interaction by age, education level, and area of residence. Data are presented as adjusted odds ratios (ORs) and 95% CIs. Of 47 841 participants (61.3% women), 5454 (57.2% women) had established CVD and 9532 (70.5% women) had a high estimated 10-year CVD risk (≥10%). Only 48.5% and 48.6% of women and 39.3% and 59.8% of men were on any kind of blood pressure (BP)-lowering medication, lipid-lowering medication, or antiplatelet therapy for primary and secondary prevention, respectively. Women with established CVD were significantly less likely than men to receive BP-lowering medications (OR, 0.79 [95% CI, 0.65-0.95]), lipid-lowering medications (OR, 0.69 [95% CI, 0.56-0.84]), antiplatelets (OR, 0.53 [95% CI, 0.45-0.62]), or any CVD prevention medication (OR, 0.62 [95% CI, 0.52-0.73]). Women with established CVD, however, had better BP control (OR, 1.31 [95% CI, 1.14-1.50]) but less well-controlled low-density lipoprotein cholesterol (OR, 0.66 [95% CI, 0.57-0.76]), and were less likely to smoke (OR, 13.89 [95% CI, 11.24-17.15]) and achieve physical activity targets (OR, 1.92 [95% CI, 1.61-2.29]). Conversely, women with high CVD risk were less likely than men to have their BP, low-density lipoprotein cholesterol, and bodyweight controlled (OR, 0.46 [95% CI, 0.38-0.55]; OR, 0.60 [95% CI, 0.52-0.69]; OR, 0.55 [95% CI, 0.48-0.63], respectively), despite a higher use of BP-lowering medications (OR, 1.21 [95% CI, 1.01-1.45]). Younger patients (<65 years) with established CVD were less likely to be taking CVD preventive medications, but there were no sex differences by area of residence or education level. Large and variable gaps in primary and secondary CVD prevention exist in China, particularly for women. Effective CVD prevention requires an improved overall nationwide strategy and a special emphasis on women with established CVD, who have the greatest disparity and the most to benefit.

Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer’s Disease and Other Dementia Disorders

Background:Recurrent ischemic stroke (IS) increases the risk of cognitive decline. To lower the risk of recurrent IS, secondary prevention is essential.Objective:Our aim was to compare post-discharge secondary IS prevention and its maintenance up to 3 years after first IS in patients with and without Alzheimer’s disease and other dementia disorders.Methods:Prospective open-cohort study 2007–2014 from the Swedish national dementia registry (SveDem) and the Swedish national stroke registry (Riksstroke). Patients with dementia who experienced an IS (n = 1410; 332 [23.5%] with Alzheimer’s disease) were compared with matched non-dementia IS patients (n = 7150). We analyzed antiplatelet, anticoagulant, blood pressure lowering, and statin treatment as planned medication initiation at discharge and actual dispensation of medications at first, second, and third year post-stroke.Results:At discharge, planned initiation of medication was higher in patients with dementia compared to non-dementia patients for antiplatelets (OR with 95% CI for fully adjusted models 1.23 [1.02–1.48]) and lower for blood pressure lowering medication (BPLM; 0.57 [0.49–0.67]), statins (0.57 [0.50–0.66]), and anticoagulants (in patients with atrial fibrillation – AF; 0.41 [0.32–0.53]). When analysis for antiplatelets was stratified according to the presence of AF, ORs for receiving antiplatelets remained significant only in the presence of AF (in the presence of AF 1.56 [1.21–2.01], in patients without AF 0.99 [0.75–1.33]). Similar trends were observed in 1st, 2nd, and 3rd year post-stroke.Conclusions:Dementia was a predictor of lower statin and BPLM use. Patients with dementia and AF were more likely to be prescribed antiplatelets and less likely to receive anticoagulants.

Abstract WP374: High Frequency Blood Pressure Monitoring in the Acute Phase of Large Vessel Occlusion Ischemic Stroke

Introduction: Decreases in blood pressure (BP) during endovascular therapy (EVT) have been associated with infarct progression and worse outcome after large vessel occlusion (LVO) stroke. However, BP trajectories in the acute phase prior to EVT have not been well characterized. We thus used high-frequency BP and hemodynamic monitoring to create a continuous BP time trend and to determine timing of BP reductions. Methods: We prospectively enrolled patients with LVO stroke undergoing EVT. BP and cardiac hemodynamic variables were recorded every 20 seconds from emergency room admission until end of EVT using non-invasive finger plethysmography. Time trends of BP recordings were categorized into 4 windows: admission to imaging; imaging to EVT; EVT to groin puncture and groin puncture to recanalization. Episodes of hypotension (mean arterial pressure ≤ 70 mmHg) were correlated with administered medications and other potentially related interventions. Time trends in hemodynamic variables were analyzed using generalized estimating equations. Results: 25 patients underwent continuous BP monitoring (age 74±18; 68% female; mean NIHSS 12, monitoring time 8.34±2 hrs). Aggregated time series data revealed a marked BP reduction around time of imaging from which patients recovered (mean SBP 33 mmHg, duration 18 min, Fig A). A sustained decrease in BP was observed after groin puncture without return to baseline BP levels. In 62% of cases, reductions in BP were associated with BP lowering medications. A significant reduction in cardiac output (p=0.003) and increase in stroke volume variation (p=0.022) was seen across predetermined time points (Fig B &amp; C). Conclusion: In patients with LVO, marked and frequently iatrogenic BP reductions occur around time of initial imaging and may present a potential target for intervention. Changes in cardiac hemodynamic variables throughout acute stroke period suggest a potential role for fluid resuscitation for hemodynamic optimization.

Impact of Relative Change in Temperature and Atmospheric Pressure on Acute Aortic Syndrome Occurrence in France

Acute aortic syndromes (AAS) have been related to significant circadian and seasonal conditions. We used time series analyses to study the impact of meteorological variations on AAS occurrence. We retrospectively assessed 140 patients presenting with AAS over a 6-year period in a French university hospital. Average daily temperature (T) and atmospheric pressure (AP) at the location of the event were collected within the previous 10 days, and their association with AAS investigated with generalized additive models. A decrease in temperature of more than 5 °C within the previous seven days was significantly associated with an increased risk of AAS occurrence (OR equal to 1.86 [1.06; 3.44]). Subgroup analysis revealed that the risk was only significant among normotensive individuals (n = 41) free from blood pressure lowering medication (OR equal to 2.3 [1.05; 5.37]), but not among hypertensive individuals under blood pressure lowering medication despite a larger patient number (n = 99). Similarly, only among the subgroup of normotensive individuals a decrease of AP between 2 and 4 kPa within the previous 3 days was associated with an increased risk of AAS (OR equal to 2.93 [1.1; 8.15]) and an increased between 2 and 4 kPa was associated with a decreased risk (OR equal to 0.59 [0.36; 1.00]). Variations of meteorological conditions (temperature and AP) within the previous week seem to have effects on triggering AAS especially among the population free from blood pressure lowering medication.

Effectiveness of a scalable group-based education and monitoring program, delivered by health workers, to improve control of hypertension in rural India: A cluster randomised controlled trial.

BackgroundNew methods are required to manage hypertension in resource-poor settings. We hypothesised that a community health worker (CHW)–led group-based education and monitoring intervention would improve control of blood pressure (BP).Methods and findingsWe conducted a baseline community-based survey followed by a cluster randomised controlled trial of people with hypertension in 3 rural regions of South India, each at differing stages of epidemiological transition. Participants with hypertension, defined as BP ≥ 140/90 mm Hg or taking antihypertensive medication, were advised to visit a doctor. In each region, villages were randomly assigned to intervention or usual care (UC) in a 1:2 ratio. In intervention clusters, trained CHWs delivered a group-based intervention to people with hypertension. The program, conducted fortnightly for 3 months, included monitoring of BP, education about hypertension, and support for healthy lifestyle change. Outcomes were assessed approximately 2 months after completion of the intervention. The primary outcome was control of BP (BP < 140/90 mm Hg), analysed using mixed effects regression, clustered by village within region and adjusted for baseline control of hypertension (using intention-to-treat principles). Of 2,382 potentially eligible people, 637 from 5 intervention clusters and 1,097 from 10 UC clusters were recruited between November 2015 and April 2016, with follow-up occurring in 459 in the intervention group and 1,012 in UC. Mean age was 56.9 years (SD 13.7). Baseline BP was similar between groups. Control of BP improved from baseline to follow-up more in the intervention group (from 227 [49.5%] to 320 [69.7%] individuals) than in the UC group (from 528 [52.2%] to 624 [61.7%] individuals) (odds ratio [OR] 1.6, 95% CI 1.2–2.1; P = 0.001). In secondary outcome analyses, there was a greater decline in systolic BP in the intervention than UC group (−5.0 mm Hg, 95% CI −7.1 to −3.0; P < 0.001) and a greater decline in diastolic BP (−2.1 mm Hg, 95% CI −3.6 to −0.6; P < 0.006), but no detectable difference in the use of BP-lowering medications between groups (OR 1.2, 95% CI 0.8–1.9; P = 0.34). Similar results were found when using imputation analyses that included those lost to follow-up. Limitations include a relatively short follow-up period and use of outcome assessors who were not blinded to the group allocation.ConclusionsWhile the durability of the effect is uncertain, this trial provides evidence that a low-cost program using CHWs to deliver an education and monitoring intervention is effective in controlling BP and is potentially scalable in resource-poor settings globally.Trial registrationThe trial was registered with the Clinical Trials Registry-India (CTRI/2016/02/006678).

For which patient subgroups are there positive outcomes from a medication review? A systematic review.

Background:A medication review is a possibility to assess and optimise a patient’s medicine. A model that includes a medication review and a follow-up seem to provide the best results. However, it is not known whether specific subgroups of patients benefit more from a medication review than others.Objective:This literature review summarises the evidence that is available on which patient subgroups exist positive outcomes from a medication review carried out in a primary care setting.Methods:We performed a PICO analysis to identify keywords for setting, medication review and effect. We then conducted a search using the PubMed database (2004 to 2019) to identify studies relevant for our investigation. A screening process was carried out based on either title or abstract, and any study that matched the aim and inclusion criteria was included. All matching studies were obtained and read, and were included if they met predefined criteria such as study design, medication review and primary care. The studies were divided into subgroups. First, each subgroup was divided according to the studies’ own definition. Secondly, each subgroup was allocated as either risk patients if the subgroup described a specific patient subgroup or risk medication, if the subgroup was defined as using a specific type of medication. This was done after discussion in the author group.Results:28 studies from a total of 935 studies were included. Identified studies were divided into either risk patients; frail, recently discharged or multimorbid patients, or risk medication; heart medication, antithrombotic medication, blood pressure lowering medication, antidiabetic medication, anti-Parkinson medication or medication increasing the risk of falls. The subgroups identified from a medication review in primary care were defined as being frail, recently discharged from hospital or multimorbid (risk patients), or defined as patients using anticoagulant or blood pressure lowering medication (risk medication). Most of the medication reviews in the studies that showed an economic effect included at least one follow-up and were delivered by a pharmacist.Conclusions:The literature review demonstrates that medication reviews delivered by pharmacists to specific subgroups of patients are a way of optimising the economic effect of medication reviews in primary care. This is obtained by reducing health-related costs or the number of contacts with primary or secondary health care services.

The effect of intensive hemodialysis on LVH regression and blood pressure control in ESRD patients.

Introduction:Cardiovascular diseases are considered the major cause of death in dialysis patients with end-stage renal disease (ESRD). Recently, intensive hemodialysis has increasingly used and replaced conventional hemodialysis. The present study aimed to evaluate the effect of intensive hemodialysis on LVH regression and blood pressure control.Methods:The present study is self-control, pre- and post-intervention clinical trial on hemodialysis ESRD patients with hypertension (52.5% female with a mean age of 55.55 ± 12.96), who were admitted to Imam Khomeini Hospitals, Golestan Ahvaz in 1396. All patients underwent intensive hemodialysis treatment 4 times a week for 2 months. 2-D color Doppler echocardiography was performed for all patients before the intervention and following 2 months of intensive hemodialysis. The results of chest echocardiographic were used to determine left ventricular thickness.Results:In this study, 40 patients with hypertension were studied. The results of this study showed a significant decrease (P < 0.0001) in the levels of LVH, SBP, DBP and mean BP after intervention in ESRD patients. The level of LVH was decreased from 15.42 ± 1.67 mmHg to 13.86 ± 1.39 mmHg, SBP from 161.50 ± 12.16 mmHg to 141.12 ± 8.87 mmHg, DBP from 25.25 ± 5.15 mmHg to 81/75 ± 2.89 mmHg, and mean BP from 114.66 ± 6.82 mmHg to 101/54 ± 3.98 mmHg.Conclusion:Based on the results, it can be concluded that intensive hemodialysis resulted in improved LVH regression and blood pressure control, and fewer requirements for blood pressure-lowering medications.

Factors Associated With Treatment and Control of Hypertension in a Healthy Elderly Population Free of Cardiovascular Disease: A Cross-sectional Study.

Despite readily available treatments, control of blood pressure (BP) with population aging remains suboptimal. Further, there are gaps in the understanding of the management of high BP in the aged. We explored antihypertensive treatment and control among elderly hypertensive participants free from overt cardiovascular disease (CVD), and identified factors related to both "untreated" and "treated but uncontrolled" high BP. We analyzed baseline data from 19,114 individuals aged ≥65 years enrolled from Australia and United States (US) in the ASPirin in Reducing Events in the Elderly study. Hypertension was defined as an average systolic/diastolic BP ≥140/90 mm Hg and/or the use of any BP lowering medication. "Controlled hypertension" was defined if participants were receiving antihypertensive medication and BP <140 and 90 mm Hg. Descriptive analyses were used to summarize hypertension control rates; logistic regression was used to investigate relationships with treatment and BP control. Overall, 74% (14,213/19,114) of participants were hypertensive; and of these 29% (4,151/14,213) were untreated. Among those treated participants, 53% (5,330/10,062) had BP ≥140/90 mm Hg. Participants who were untreated were more likely to be men, have higher educational status, and be in good physical health, and less likely to have significant comorbidities. The factors related to "treated but uncontrolled" BP included older age, male, Black race (vs. White), using antihypertensive monotherapy (vs. multiple) and residing in Australia (vs. US). High levels of "untreated" and "treated but uncontrolled" BP occur in healthy elderly people without CVD, suggesting there are opportunities for better BP control in the primary prevention of CVD in this population. NCT01038583.

Identifying and treating high blood pressure in men under 55 years with grade 1 hypertension: the TREAT CASP study and RCT

Background There is uncertainty regarding whether or not younger (i.e. aged &lt; 55 years), low-risk patients with grade 1 hypertension (i.e. a clinic blood pressure of 140–159/90–99 mmHg) should be treated with blood pressure-lowering medication. This is a heterogeneous group of patients because of variation in systolic/pulse pressure amplification from the central aorta to the brachial artery. It is hypothesised that within grade 1 hypertension, patients can be divided into those with high central aortic systolic pressure and those with low central aortic systolic pressure. Objectives The aims of this study were to (1) evaluate whether or not non-invasive central aortic systolic pressure measurement can better identify younger patients with grade 1 hypertension, who are more likely to have an increased left ventricular mass index; and (2) determine whether or not blood pressure lowering regresses early cardiac structural change in patients with high central aortic systolic pressure. Setting A university hospital with satellite primary care recruitment sites. Participants A total of 726 men (aged 18 to &lt; 55 years) were screened to identify 162 men with grade 1 hypertension and low or high central aortic systolic pressure. Blood pressure status was classified according to seated clinic blood pressure, central aortic systolic pressure and 24-hour ambulatory blood pressure. Design (1) Evaluating the strength of the correlation between central aortic systolic pressure, clinic blood pressure and 24-hour ambulatory blood pressure with left ventricular mass index in 162 patients; (2) a 12-month randomised controlled trial in patients with grade 1 hypertension and high central aortic systolic pressure (i.e. a central aortic systolic pressure of ≥ 125 mmHg) (n = 105), using a prospective, open, blinded, end-point design; and (3) a 12-month observational study in 57 patients with grade 1 hypertension and low central aortic systolic pressure (i.e. a central aortic systolic pressure of &lt; 125 mmHg). Interventions Randomised controlled trial – patients with high central aortic systolic pressure randomised to blood pressure lowering medication (50–100 mg of losartan ± 5–10 mg of amlodipine once daily) versus usual care (no treatment) for 12 months. Main outcomes Randomised controlled trial primary end point – change in left ventricular mass index as measured by cardiac magnetic resonance imaging, comparing treatment with no treatment. Results (1) At baseline, left ventricular mass index was higher in men with high central aortic systolic pressure than in those with low central aortic systolic pressure (mean ± standard deviation 67.9 ± 8.8 g/m2 vs. 64.0 ± 8.5 g/m2; difference 4.0 g/m2, 95% confidence interval 1.1 to 6.9 g/m2; p &lt; 0.01). Central aortic systolic pressure was not superior to clinic blood pressure as a determinant of left ventricular mass index. Univariate analysis, regression coefficients and slopes for left ventricular mass index were similar for clinic systolic blood pressure, ambulatory systolic blood pressure and central aortic systolic pressure. (2) In the randomised controlled trial, blood pressure-lowering treatment reduced central aortic systolic pressure (–21.1 mmHg, 95% confidence interval – 24.4 to –17.9 mmHg; p &lt; 0.001) and clinic systolic blood pressure (–20.0 mmHg, 95% confidence interval – 23.3 to –16.6 mmHg; p &lt; 0.001) versus no treatment. Treatment was well tolerated and associated with a greater change (i.e. from baseline to study closeout) in left ventricular mass index versus no treatment [–3.3 g/m2 (95% confidence interval –4.5 to –2.2 g/m2) vs. –0.9 g/m2 (95% confidence interval –1.7 to –0.2 g/m2); p &lt; 0.01], with a medium-to-large effect size (Cohen’s d statistic –0.74). (3) Patients with low central aortic systolic pressure had no significant change in left ventricular mass index after 12 months (mean change –0.5 g/m2, 95% confidence interval –1.2 to 0.2 g/m2; p = 0.18). Conclusions Men with grade 1 hypertension and high central aortic systolic pressure tended to have higher clinic blood pressure and more hypertension-mediated cardiac structural change than those with low central aortic systolic pressure. Central aortic systolic pressure was not superior to clinic blood pressure or ambulatory blood pressure at stratifying risk of increased left ventricular mass index. Blood pressure-lowering treatment led to a regression of left ventricular mass index in men with grade 1 hypertension and high central aortic systolic pressure compared with no treatment. Limitations The study was limited to a moderate sample of men and there was a low prevalence of very high amplification. Future work Evaluating effects of blood pressure lowering on cardiac function. Trial registration Current Controlled Trials ISRCTN09502665. Funding This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership and will be published in full in Efficacy and Mechanism Evaluation; Vol. 6, No. 13. See the NIHR Journals Library website for further project information.

Lower 24-h urinary sodium excretion is associated with hypertension control: the 2010 Heart Follow-Up Study.

Among individuals with hypertension, controlling high blood pressure (BP) reduces the risk for cardiovascular events and death. Reducing dietary sodium can help achieve BP control. The study aim was to use a population-based sample utilizing the gold-standard for urinary sodium to quantify the degree with which sodium was independently associated with BP control among individuals with hypertension. Participants included 1 568 adults from the Heart Follow-Up Study, a New York City population-based representative study conducted in 2010. Participants collected urine for 24 hours and had BP and other anthropometrics measured. Hypertension was defined as systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or being on BP lowering medication. Sodium intake (mg/day) was measured from a single 24-hour urine collection. Hypertension prevalence was 30.8%. Among those with hypertension, 64.6% were aware, 56.3% were treated, and 40.3% were controlled. Among those treated for hypertension, 73.0% were controlled. Mean sodium intake among those with hypertension was 3 564 mg/day. From multivariable adjusted logistic regression models, each 500mg decrease in 24-hour urinary sodium excretion was associated with a 18% higher odds of hypertension control among those with hypertension (1.18, 95% CI: 1.07, 1.30). In New York City, approximately one in three people has hypertension with a majority uncontrolled. Sodium intake among those with hypertension was 55% greater than recommended upper limit of 2 300 mg per day. Among individuals with hypertension, lower sodium intake was associated with hypertension control.

P1943Ambient temperature and seasonal effects on blood pressure in 2.6 million Australians

Abstract Background There is evidence that blood pressure (BP) levels vary considerably from season to season, due principally to variation in ambient temperature. This gives the potential for both under- and over-treatment if BP lowering medications are not varied seasonally, but is not acknowledged in clinical guidelines. We will describe the seasonal variation in BP and assess the association between systolic blood pressure (SBP) and outdoor maximum ambient temperature in Australia. Methods The primary care data is an extract from MedicineInsight, a national general practice data program developed and managed by NPS MedicineWise, which extracts deidentified data from almost 10% of all Australian general practices. We included patients aged 30–90 years with at least one BP measure recorded from 1 Jan 2010 to 1 Aug 2017. Australian Bureau of Meteorology daily max temperature is linked by matching observation dates and location to nearest weather station. Decomposition of the mean will determine seasonal variation. Multiple linear regression was used to estimate the associations between max temperature and SBP with adjustment for age, sex, socioeconomic index, current smoking, comorbidities, BP lowering medication use, lipid lowering medication use and year of BP measurement. Results The study population includes 2.6 million people, mean age 55 years (standard deviation [SD] 16.3). Fifty-five percent are female, over a third of the cohort reside in New South Wales, and 62.4% reside in major Australian cities. The mean (SD) temperature was 23°C (6.6). There was a mean (SD) of 7 (11.4) BP measurements per person over the study period, median 3 measures (interquartile range 1–8). A quarter had a history of hypertension, 8% had a history of cardiovascular disease, and 8% had a history of diabetes. Twenty-six percent had at least one prescription for BP lowering therapy. The average monthly SBP for the cohort demonstrated strong seasonal variation with higher values in winter. The population mean varies by 3mmHg SBP between seasons across Australia, ranging from 1.7mmHg in the Northern Territory to 3.5mmHg in South Australia (range of mean maximum temperature 3°C [30–33] and 14°C [15–29] for the capital cities respectively). Each 10°C increase in max outdoor temperature was associated with a 1.8mmHg [95% CI 1.80–1.83] lower mean SBP. The proportion of people with SBP&gt;140mmHg varied by season, irrespective of age, sex and use of BP lowering treatment. For example, among those treated control rates varied between 70 and 81%, and among those not treated between 78 and 85% (Figure). Blood pressure seasonality in Australia Conclusions BP control rates vary considerably by season. These findings have implications for the reliable diagnosis of hypertension, and suggest seasonal adjustments in treatment should be considered for some patients. The clinical and public health relevance of this phenomenon is expected to increase with increasing climate variability. Acknowledgement/Funding National Health and Medical Research Council Australia, National Heart Foundation Australia

P4557Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: a cross-sectional study

Abstract Introduction Despite readily available treatments, control of high blood pressure (BP) in the ageing population remains suboptimal. Gaps in understanding the management of high BP amongst the elderly exist, as most studies have been in predominantly middle-aged populations. Purpose We explored pharmacological BP lowering treatment and control among elderly hypertensive participants free from overt cardiovascular disease (CVD), and identified factors related to both “untreated” and “treated but uncontrolled” high BP. Methods We analyzed baseline data from 19,114 individuals aged ≥65 years enrolled from Australia and the US in the ASPirin in Reducing Events in the Elderly (ASPREE) study. Hypertension was defined as an average systolic/diastolic BP ≥140/90 mmHg and/or use of any BP-lowering medication. `Controlled hypertensives” were those receiving BP-lowering medication and with BP &lt;140/90 mmHg. Descriptive analyses were used to summarize hypertension control rates; logistic regression was used to investigate relationships with treatment and BP control. Results Overall, 74% (14,213/19,114) of participants were hypertensive, and of these 29% (4,151/14,213) were untreated. Among those treated, 47% (4,732/10,062) had BP &lt;140/90 mmHg. Participants who were untreated were more likely to be men, have higher educational status, and be in good physical health, and less likely to have significant comorbidities. The factors related to “treated but uncontrolled” hypertension included older age, being men, Black race (versus White), using BP lowering monotherapy and residing in Australia (versus US) (Figure 1). Conclusion(s) There were high levels of “untreated” and “treated but uncontrolled” BP, in an otherwise healthy elderly population, suggesting that opportunities for better BP control exist through targeting intervention to high-risk individuals. Acknowledgement/Funding National Institute on Aging and the National Cancer Institute at NIH; NHMRC Australia, Monash University, Victorian Cancer Agency (Australia)

Diuretics and skin cancer

Diuretics and skin cancer

P4412Association of sleep duration with cardio-metabolic risk leading to development of atherosclerotic cardiovascular disease

Abstract Background Sleep duration, mostly of short duration, has emerged as a potential factor in adverse cardio-metabolic risk. We investigated the relationship between sleep duration and cardio-metabolic risk leading to atherosclerotic cardiovascular disease (ASCVD). Purpose We examined the association between sleep duration and cardio-metabolic risk in Japanese men. Methods This cross-sectional study was conducted using a sample of 6,907 apparent healthy men who had undergone medical examinations at the Health Planning Center of Nihon University Hospital between April, 2015 and May, 2016. The relationship between waist circumference, homeostasis model assessment of insulin resistance (HOMA-IR), HbA1c, non-high-density lipoprotein cholesterol (non-HDL-C) level, and sleep duration was evaluated. Results Both unusually short and long sleep durations were associated with waist circumference, impaired glucose tolerance and high non-HDL-C level (Figure). Compared with men sleeping 7 to 8 hours, the relative risk of abdominal obesity (defined according to the Japanese criteria for metabolic syndrome as a waist circumference of 85cm≥) among men sleeping ≥8 h was 1.27 (95% Confidence interval (CI), 1.05–1.55, p&lt;0.01); the relative risk of a high HOMA-IR (2.0≥) level among men sleeping &lt;5 h was 1.43 (95% CI, 1.00–2.05, p&lt;0.05); among men sleeping ≥8 h the relative risk was 1.38 (95% CI, 1.08–1.77, p=0.01); the relative risk of a HbA1c level of ≥5.6% (defined as “high” by a specialized life style checkup program for the detection of symptoms of metabolic syndrome in Japan) among men sleeping &lt;5 h was 1.39 (95% CI, 1.01–1.65, p&lt;0.05); the relative risk of a non-HDL-C level of ≥170 mg/dL (defined as “high” by the Japanese Arteriosclerosis Society based on a lipid control target value for the primary prevention of ASCVD) among men sleeping ≥8 was 1.40 (95% CI, 1.13–1.76, p&lt;0.01). These analyses were adjusted for age, psychological stress, and the use of cholesterol-lowering, blood-pressure lowering, and anti-diabetic medications. Conclusion The results suggest that unusually short and long sleep durations may increase cardio-metabolic risk. To further reduce the risk of ASCVD, it may be of particular importance to emphasize adequate sleep duration.

P2684Blood pressure lowering by using a self-care focused smartphone application for patients after myocardial infarction

Abstract Background We have previously shown that complementing traditional cardiac rehabilitation (CR) with a web-based smartphone application designed to support self-control of risk factors can improve secondary prevention outcomes, including lower blood pressure (BP). Purpose To explore possible explanations for better BP control among patients with myocardial infarction (MI) receiving access to a smartphone application as a complement to traditional CR, compared to patients receiving traditional CR alone. Methods Data from a multi-centre randomized controlled trial that included 150 patients with MI (81% men, 60.4±8.8 years) was used. All patients participated in traditional CR. In addition, patients in the intervention group (APP, n=101) had access to the application. Patients received automated positive feedback on normal values and all registered data was viewed by CR nurses twice weekly. As previously reported, APP patients achieved a 9 mmHg larger reduction in systolic BP than usual care (UC) patients at 2-months follow-up (p=0.02). In the current analysis we assessed differences between APP and UC patients in the number of visits and telephone contacts with the CR clinic, number of reported BP measurements and number and type of interventions on account of out-of-range BP during the first 6 months of follow-up, using Mann-Whitney and chi-square tests. Results There was no difference in the median (IQR) number of visits to a CR nurse or physician (APP 2 (2–3) vs UC 2 (2–3), p=0.8) or telephone contacts ((APP 2 (1–4) vs UC 2 (1–4), p=0.8) between the groups. Approximately one in ten telephone contacts were initiated because of BP, with no difference between the groups (p=0.8). Out of 101 APP patients 75 reported BP values through the application, ranging from 1–175 BP values/patient (median 6 (IQR 0–34)). Most measurements (90%) were normal. Grouping clinic visits, telephone contacts due to BP and BP reports through the application as a composite for the number of BP measurements the CR personnel were exposed to during follow-up, there was a significant difference between the groups (APP 9 (4–36) vs UC 3 (2–3), p&lt;0.0001). There was a small non-significant difference between the groups in the proportion of patients where an intervention was performed by the CR nurse on account of out-of-range BP (i.e. medication adjustments, new measurement scheduled) (APP 22% vs UC 12%, p=0.1). Conclusion While CR personnel were exposed to significantly more BP measurements from patients using a self-care focused smartphone application as a complement to traditional CR, most BP measurements reported through the application were normal and there was no difference in the number of interventions performed on account of out-of-range BP values. Automated positive feedback on in-range BP measurements, increased patient responsibility with better adherence to BP lowering medication could be possible explanations to improved BP control. Acknowledgement/Funding The faculty of Medicine, Lund University, Lund, Sweden

P6254Care cascade of hypertension in people living with HIV

Abstract Background Life expectancy of people living with HIV (PLHIV) has been increasing since the advent of antiretroviral therapy. However, prevalence of non-communicable diseases (NCD) and associated deaths has followed the same trend. From these NCDs, those of cardiovascular origin have become the most prevalent among PLHIV. Purpose In this study we delineate a cascade of care for hypertension screening, diagnosis, treatment, drug adherence and control in PLHIV. Methods Male and female patients diagnosed with HIV above 40 years of age attending to an outpatient clinic of a reference tertiary care centre for infectious diseases were cross-sectionally screened for hypertension through blood pressure (BP) measurement during outpatient consultation. Results A total of 298 subject were enrolled. Of these, 107 (35.9%) presented elevated BP consistent with hypertension according to national guidelines. Of these, only 36 (33.6%) were aware of the diagnosis, 19 (17.7%) were on regular cardiological follow-up, 17 (15.8%) were under treatment and 11 (10.2%) responded to be adherent to BP lowering medication. Care Cascade HIV_HTN Conclusions Steep decline was revealed in several steps of the cascade of care, especially regarding the awareness level. Integrative methods for NCD and HIV care are urgently needed. Early screening of hypertension, diagnosis, treatment, adherence and ongoing BP control should be equal targets in HIV care. Finally, there is an urgent need to encourage HIV primary care and infectious disease health professionals to early screen for cardiovascular outcomes. Acknowledgement/Funding Fundação de Amparo à Pesquisa do Estado do Amazonas – FAPEAM

Impact of hypertension phenotypes on the office and 24-h pulse wave velocity and augmentation index in individuals with or without antihypertensive medication use.

Data on the association of blood pressure (BP) phenotypes with office and out-of-office markers of vascular stiffness and pressure wave reflection are sparse. This study investigated office and 24-h measures of brachial BP, pulse wave velocity (PWV), and central augmentation index (AIx) across hypertension phenotypes among individuals not using BP-lowering medications [normotension (NT), white-coat hypertension (WH), masked hypertension (MH) and sustained hypertension (SH)] and those using BP-lowering medications [controlled hypertension (CH), white-coat uncontrolled hypertension (WUCH), masked uncontrolled hypertension (MUCH) and sustained uncontrolled hypertension (SUCH)]. We evaluated 454 untreated (age = 45 ± 15 years, 50% males) and 238 treated (age = 52 ± 15 years, 45% males) individuals who underwent office and 24-h brachial BP, PWV, and AIx measures using a Mobil-O-Graph PWA monitor. In the analysis adjusted for age and sex, WH had higher (p < 0.05) office PWV (7.53 ± 0.09 vs 6.89 ± 0.05), office AIx (27.9 ± 1.3 vs 23.8 ± 0.8), and daytime AIx (24.6 ± 0.7 vs 22.7 ± 0.4) compared with those of NT, while WUCH had higher (p < 0.05) office PWV (8.28 ± 0.11 vs 7.43 ± 0.08) and 24-h PWV (7.54 ± 0.09 vs 7.21 ± 0.07) than those of CH. MH had higher (p < 0.05) 24-h PWV (7.00 ± 0.09 vs 6.69 ± 0.04) and 24-h AIx (24.3 ± 0.9 vs 21.9 ± 0.4) than those of NT, whereas MUCH had higher (p < 0.05) 24-h PWV (7.64 ± 0.13 vs 7.21 ± 0.07) than that of CH. Lastly, SH or SUCH had significantly higher office and 24-h PWV and AIx than those of NT and CH, respectively. In conclusion, these results suggest that individuals with masked BP phenotypes are more predisposed to have adverse out-of-office vascular characteristics, while individuals with white-coat phenotypes have adverse office and out-of-office vascular characteristics compared with those of individuals with normal BP levels.